ArticleCureus2025
Association Between Kounis Syndrome and Allergy-Associated Coronary Events: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative clinical features of antibiotic-associated Kounis syndrome and non-Kounis allergic coronary events: a disproportionality analysis using U.S. Food and Drug Administration Adverse Event Reporting System.Journal of pharmaceutical health care and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Kounis syndrome (KS) is an allergy-induced acute coronary syndrome (ACS); however, the lack of established diagnostic criteria raises concerns regarding underdiagnosis. Misclassification of allergy-associated coronary events as non-KS conditions may hinder appropriate treatment and risk stratification. This study aimed to elucidate the clinical differences between KS and allergy-associated coronary events not diagnosed as KS (non-KS) to improve diagnostic recognition and clinical awareness. Methods Using the Japanese Adverse Drug Event Report database (2012Q3-2024Q2), we compared patient backgrounds, suspected drugs, and clinical features between the KS (n = 130) and non-KS (n = 115) groups. Multivariate analysis identified predictors of non-KS events. Results The KS group was associated with anesthetics and contrast media (e.g., iodinated agents such as iopamidol and iohexol), whereas the non-KS group was associated with heparin and the coronavirus disease 2019 vaccine. The non-KS group showed higher mortality and prevalence of specific underlying diseases than the KS group. Multivariate analysis identified heparin-induced thrombocytopenia (odds ratio (OR), 198.38; 95% confidence interval (CI), 39.45-3621.42), antineoplastic drug use (OR, 20.30; 95% CI, 6.68-76.87), fatal outcomes (OR, 11.98; 95% CI, 4.63-34.28), shock (OR, 10.02; 95% CI, 2.13-73.12), and ACS (OR, 5.66; 95% CI, 1.59-21.53) as independent predictors of non-KS events (all P < 0.05; area under the curve, 0.891). Conclusions Patients without KS often have severe underlying conditions and worse outcomes, suggesting a potential oversight of KS in clinical practice. These findings underscore the importance of improving the diagnostic clarity for KS and may contribute to future efforts to refine diagnostic criteria and pharmacovigilance practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.